Joyce Samuel

  • Citations Per Year
Learn More
BACKGROUND We conducted a multicenter randomized phase II trial to evaluate two schedules of single-agent docetaxel in the first-line treatment of elderly and performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC). METHODS Patients 70 years of age and older with a PS 0-1 or patients of any age and PS 2 were randomly assigned(More)
7057 Background: Docetaxel has been used in elderly and PS 2 pts with advanced NSCLC with acceptable toxicity. However, myelosuppression can be severe on the every 3-week schedule. Docetaxel weekly appears to have similar efficacy and less hematologic toxicity. Practice varies widely and no comparative study has yet been completed in the US. METHODS(More)
A 46-year-old African American man presented with weakness and numbness in both legs and pain in the left upper chest of 3 weeks’ duration. He noted no change in urinary or bowel habits,but he had anorexia with more than 30 pounds of weight loss over 3 months. He had no fever or night sweats and no cardiac, respiratory, or gastrointestinal symptoms, but he(More)
7283 Background: Incidence of SCLC usually varies from 17-29% from biopsy/cytology specimens. In the SEER data, SCLC comprises of 18% of all primary lung cancer. Recently it was observed that the incidence is increasing especially in women. This study was done to evaluate SCLC incidence in an urban hospital serving predominantly African-American population.(More)
7306 Background: Brain is one of the common areas of metastases occurring in 20-50% of patients with lung cancer. They are seen more often in small cell lung cancer (SCLC) than in non-small cell lung cancer (NSCLC). This study was done to evaluate the incidence of various types of lung cancer causing brain mets in an urban hospital serving predominantly(More)